Incidence and Associated Factors of HIV Drug Resistance in Chinese HIV-Infected Patients Receiving Antiretroviral Treatment

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Xing, Hui ^a   Wang, Xia ^a   Liao, Lingjie ^a   Ma, Yanling ^b   Su, Bin ^c   Fu, Jihua ^d   He, Jianmei ^e   Chen, Lin ^f   Pan, Xiaohong ^g   Dong, Yonghui ^h   Liu, Wei ⁱ   Hsi, Jenny H ^a   Yang, Liting ^a   Ruan, Yuhua ^a   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b YUNNAN PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c Anhui Center for Disease Control and Prevention   (China)

^d Shandong Center for Disease Control and Prevention   (China)

^e Hunan Center for Disease Control and Prevention   (China)

^f Shenzheng Center for Disease Control and Prevention   (China)

^g ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^h Xinjiang Center for Disease Control and Prevention   (China)

ⁱ GUANGXI CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DEVELOPED COUNTRY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POPULATION RISK; PROSPECTIVE STUDY; RISK FACTOR; VIRUS LOAD; ANTIVIRAL RESISTANCE; BLOOD; CHINA; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MUTATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHINA; COHORT STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; VIRAL LOAD;

EID: 84876966697     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062408     Document Type: Article

References (26)

1. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, et al. (1999) Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 160: 659-665.
2. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
3. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, et al. (2009) Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 9: 409-417.
4. Wang X, Xing H, Ruan Y, Liao L, Zhou H, et al. (2012) Effect of viral load and drug resistance on mortality among Chinese HIV-infected patients receiving antiretroviral treatment. Journal of Antivirals & Antiretrovirals 4: 5.
5. Xing H, Ruan Y, Li J, Shang H, Zhong P, et al. (2013) HIV Drug Resistance and Its Impact on Antiretroviral Therapy in Chinese HIV-Infected Patients. PLoS One 8: e54917.
6. Audelin AM, Lohse N, Obel N, Gerstoft J, Jorgensen LB, (2009) The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish cohort study 1999-2005. Antivir Ther 14: 995-1000.
7. Gill VS, Lima VD, Zhang W, Wynhoven B, Yip B, et al. (2010) Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clin Infect Dis 50: 98-105.
8. Vercauteren J, Deforche K, Theys K, Debruyne M, Duque LM, et al. (2008) The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal. Retrovirology 5: 12.
9. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53Suppl 1: S10-14.
10. Zhong P, Pan Q, Ning Z, Xue Y, Gong J, et al. (2007) Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 23: 847-856.
11. Liu TF, Shafer RW, (2006) Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 42: 1608-1618.
12. Johannessen A, Naman E, Kivuyo SL, Kasubi MJ, Holberg-Petersen M, et al. (2009) Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 9: 108.
13. Chang HM, Tsai HC, Lee SS, Wann SR, Chen YS, (2012) Noncirrhotic portal hypertension associated with didanosine: a case report and literature review. Jpn J Infect Dis 65: 61-65.
14. Ma Y, Zhao D, Yu L, Bulterys M, Robinson ML, et al. (2010) Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 50: 264-271.
15. Gong J, Wang XQ, Tong X, Shen XH, Yang RG, (2011) Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. Virol Sin 26: 386-392.
16. Yuan Y, Xing H, Wang XY, Liu CH, Yang LT, et al. (2011) [The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province]. Zhonghua Yu Fang Yi Xue Za Zhi 45: 619-624.
17. Wang H, Zhang HM, Jiang Q, Peng QL, Tan Y, et al. (2010) [Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy]. Zhonghua Yi Xue Za Zhi 90: 584-587.
18. Zhang Y, Dou Z, Sun K, Ma Y, Chen RY, et al. (2012) Association between missed early visits and mortality among patients of china national free antiretroviral treatment cohort. J Acquir Immune Defic Syndr 60: 59-67.
19. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf. Accessed May 16, 2011.
20. Ruan Y, Xing H, Wang X, Tang H, Wang Z, et al. (2010) Virologic outcomes of first-line HAART and associated factors among Chinese patients with HIV in three sentinel antiretroviral treatment sites. Trop Med Int Health 15: 1357-1363.
21. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, et al. (2003) Dramatic improvement in survival among adult Brazilian AIDS patients. AIDS 17: 1675-1682.
22. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, et al. (2004) The prevalence of antiretroviral drug resistance in the United States. AIDS 18: 1393-1401.
23. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, et al. (1998) Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279: 1984-1991.
24. Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191: 339-347.
25. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, et al. (2009) Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 360: 1815-1826.
26. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, et al. (2010) Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 363: 257-265.